About
Key Milestones
Inventvacc was founded by Dr. Kapre & Mr. Pradip Ghate in 2016 to develop vaccines for rare diseases currently affecting more than 400 million people worldwide.
Our mission and focus is to empower healthy living by developing unique, efficacious and affordable vaccines for the populations most in need. Over the years, the company has grown from a small R&D lab, operating out of Vancouver, Canada, to
a
multinational commercial operations with an innovative pipeline.
Timeline 2016 - 2021
Click on the dots below each date to navigate the timeline
Use the arrows to see more of the timeline
Team
A team of industry veterans & partners with more than 35 years’
experience in the vaccine business responsible for:
Dr. Subhash Kapre PHD
Chairman
Subhash Kapre, PhD heads the InventVacc board as Chairman. His experience encompasses multiple senior executive vice president positions at Serum Institute of India Pvt. Ltd. (SIIPL), which measured by volume, is the world’s largest vaccine manufacturer.
Pradip Ghate
Chief Executive Officer
Pradip Ghate has over three decades of international experience working in developing and developed countries in Project and Operations management for Aseptic Sterile operations of biological and pharmaceutical products.
Yves Leurquin
Chief Business Officer
Yves Leurquin leads partnerships, capital formation and structural growth at Inventvacc. Before joining Inventvacc, Yves Leurquin was Global Head of Pricing and Tender Management for Takeda’s Vaccine Business Unit.
Dr. Luis Barreto M.B.B.S., M.D., M.H.Sc
Senior Scientific Advisor
Dr. Luis Barreto is the President of Dr. Luis Barreto & Associates, a consultancy firm specializing in vaccine development, immunization, science policy, global health and biotechnology.
Commitment to Canada
InventVacc was born In Canada and is committed to develop and manufacture Haemophilus Influenzae Type A (Hia) vaccine in collaboration with the National Research Council of Canada (NRC) and the Public Health Agency of Canada (PHAC). InventVacc is also committed to develop & manufacture innovative,
affordable vaccines in Montreal
Haemophilus influenzae type a (Hia)
Each year in Canada, especially in the North and in Indigenous communities, many infants and immunocompromised adults are at risk of Hia. The bacterial infection can result in pneumonia, meningitis, septic arthritis, and bloodstream infections.
Since the late 1990s, there has been an emergence of Hia infections, especially in Indigenous communities in the northern regions of Canada and Alaska associated with significant morbidity and approximately a 10% mortality rate.
Several cases per year are being recorded in Canada and the disease is spreading to other regions of the globe which led to the World Health Organization exploring with InventVacc and NRC to make this vaccine available.
GLOBAL EPIDEMIOLOGY OF HIA
- Many reported cases
- One or few reported cases
InventVacc Biologics Inc. and its partner Inventprise are committed to developing and manufacturing vaccines for this rare and neglected disease with the objective of preventing infections and saving lives.
